tbuckley/cabot-search huggingface dataset:
Abstract 020: NT-proBNP, hs-Troponin T and Incident Venous Thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study
Authors: Pamela L Lutsey, Vijay Nambi, Mary Cushman, Susan R Heckbert, Christopher R DeFilippi, Christie Ballantyne, Aaron R Folsom
Journal: Circulation (2013)

Background: NT-pro B-type natriuretic peptide (NT-proBNP) and high sensitivity cardiac troponin T (TnT) are important biomarkers for CHD and HF risk, but whether they are related to incidence of venous thromboembolism (VTE) is unknown. NT-proBNP is a marker of volume overload; volume overload may contribute to VTE risk via increased stasis and thrombogenesis. TnT might relate to VTE indirectly, as a marker of vascular inflammation or endothelial dysfunction. Hypotheses: NT-proBNP and TnT are associated positively with risk of incident VTE. Methods: Data from visit 4 (1996-1998) of the prospective population-based Atherosclerosis Risk in Communities study (n = 10,735; 53-74 yrs) were used. VTE events through 2005 were identified and validated by medical record review. Cox proportional hazards regression was used to explore the relation between the biomarkers and VTE. Model 1 adjusted for age, sex, and race. Model 2 additionally adjusted for HRT use, diabetes status, BMI, eGFR, CRP, aPTT and factor VIII. Results: A total of 227 incident VTE cases accrued over a median follow-up of 8.0 yrs. Relative to participants in the lowest quintile of NT-proBNP (≤26.7 pg/mL), those in the highest quintile (≥151.3 pg/mL) were at 2.28 (95% CI: 1.47-3.54) times greater risk of incident VTE (p-trend = 0.0002), adjusted via Model 1. This association was only slightly attenuated after adjustment in Model 2 [HR: 1.98 (95% CI: 1.25, 3.13); p-trend = 0.003]. The general trend was present for both unprovoked [HR: 1.62 (95% CI: 0.70, 3.75)] and provoked VTE [HR: 2.22 (95% CI: 1.28, 3.84)] in the fully-adjusted models, though power was low when stratifying by VTE type. Participants in the highest category (≥0.014 ug/L) of TnT were also at modestly greater risk of incident VTE in Model 1 [HR: 1.99 (95% CI: 1.23, 3.21); p-trend = 0.0002] and Model 2 [HR: 1.52 (95% CI: 0.89, 2.60); p-trend = 0.03], relative to those with undetectable TnT. The association was, however, present for only provoked VTE, with no evidence of a relation for unprovoked VTE. Discussion: In this large prospective cohort, both NT-proBNP and TnT were positively associated with risk of incident VTE. For NT-proBNP, the general trend was present for both provoked and unprovoked events, while for TnT the relation was isolated to provoked VTE events. Additional research is warranted to evaluate whether NT-proBNP and TnT are related to risk of VTE, or if the associations observed were the result of uncontrolled confounding.
An expanded profile of cutaneous reactions to nonsteroidal anti-inflammatory drugs. Reports to a specialty-based system for spontaneous reporting of adverse reactions to drugs
Authors: R. S. Stern
Journal: JAMA (1984)

The nonsteroidal anti-inflammatory drugs are widely used in the United States and are a frequent cause of cutaneous reactions. Since December 1980, dermatologists have reported 135 of these drug reactions to a specialty-based Adverse Drug Reaction Reporting System. Reactions to piroxicam were most frequently reported; the majority of reactions to this drug were vesiculobullous and occurred most often in sun-exposed areas. Other reactions to nonsteroidal anti-inflammatory drugs not previously recognized include serum sickness, exfoliative erythroderma, and photosensitivity associated with sulindac; toxic epidermal necrolysis was reported with tolmetin, zomepirac sodium, and piroxicam. Fixed drug eruptions were noted with ibuprofen and naproxen, and photosensitivity was reported with sulindac and indomethacin. These findings illustrate the usefulness of a specialty-based system for spontaneous reporting of new and serious adverse reactions to drugs. (<i>JAMA</i>1984;252:1433-1437)
Abstract 3364: A study to assess the critical result reporting of the patients diagnosed with cancer at B&amp;C Medical College and Teaching Hospital
Authors: Sujan Sharma
Journal: Cancer Research (2019)

Abstract Objective: This critical value can occur while performing panels of tests at laboratory by different chemistry or blood analysers with varieties of principles. The main objective of the study was to study the process of critical result reporting and to know the way of communication and documentation done for critical value in the laboratory, ICUs and the wards.Methods: This study was prospective and non-experimental was conducted at B&amp;C Medical College and Teaching Hospital from 14.04.2018 to 14.05.2018 . Total 60 critical values samples were included. The data was collected by means of observing the critical values of inpatient and the process of reporting from the laboratory to the respective wards and ICUs.Results: Out of 60 samples included in our study, there was 100% communication to concerned treating units. For the confirmation of critical value repeat test was done in 68% of cases. In 75% of cases clinicians did follow up. Recording of a critical report in lab was done in 96% of cases and almost all of the critical values 98% were immediately reported to the respective wards by technical staffs. There was no communication in 1.6% of cases to treating units by technical staff. Majority 78% of critical values were communicated by respective wards and ICUs nurses to concerned doctors.Conclusion: Critical value can occur while performing panels of tests at laboratory and reporting such values to treating clinicians or respective wards or ICUs could help heath care providers for effective treatment of the patients and their adequate care. Note: This abstract was not presented at the meeting. Citation Format: Sujan Sharma. A study to assess the critical result reporting of the patients diagnosed with cancer at B&amp;C Medical College and Teaching Hospital [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3364.
THE PURPOSE OF THE GALLBLADDER
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CASE OF URTICARIA PIGMENTOSA FOLLOWING CHICKEN-POX.
Authors: ALBERT WOLDERT
Journal: JAMA (1899)

The patient, a male child 11 months of age, of English parentage, was presented for treatment at St. Joseph's Hospital on May 10, 1899. <h3>Family History.</h3> —His father and mother are living and in good health, and there are eight other children all of whom have been entirely free from a rash of the character hereafter described. The father and mother have never suffered from a rash of any kind, with the exception of prickly heat, and both seem to present a history free from specific disease. <h3>Personal History.</h3> —The child was born at the eighth month of gestation, there being a hard, dry labor, and version was done. The patient has been fed on the breast, has never suffered from a rash or disease of any variety until he had the chicken-pox when 3 months of age. At the time he became ill of this latter disease an epidemic
Early Neurosyphilis
Authors: Israel Kopp
Journal: New England Journal of Medicine (1948)

Invasion of the central nervous system occurs in nearly all patients during the early stages of syphilis, usually during the first year of the infection. Early neurosyphilis is essentially a leptomeningitis. It is most often asymptomatic. The knowledge of its presence is of great importance since more intensive therapy and careful observation are necessary for these patients.Early asymptomatic neurosyphilis can be detected only by spinal-fluid examination. The percentage of abnormal spinal fluids depends upon the time and frequency of the examination, ranging from 9 per cent in primary syphilis to 16 and 48 per cent in early and late . . .
A Retired Shipyard Worker with Rapidly Progressive Pulmonary Interstitial Fibrosis
Authors: Eileen V. Moy, Howard Hu, David C. Christiani
Journal: Environmental Health Perspectives (1999)

We present a case of progressive interstitial fibrosis in a retired shipyard worker who was exposed to asbestos during the postwar era of the late 1940s and 1950s, when asbestos exposures in the workplace were not regulated. Forty years later, at 63 years of age, the patient presented with restrictive lung disease. The patient was diagnosed with asbestos-related pleural disease and parenchymal asbestosis. He remained stable for the next 7 years, but then he began to manifest rapid clinical progression, which raised the possibility of an unusual variant of asbestosis, a concomitant interstitial process, or an unrelated disease. Lung biopsy was not undertaken because of the patient's low pulmonary reserve and limited treatment options. An empiric trial of oral steroids was initiated, but his pulmonary status continued to deteriorate and he died of pulmonary failure at 72 years of age. Many diseases result in pulmonary interstitial fibrosis. Ideally, open lung biopsy should be performed, but this procedure inevitably causes complications in many patients with end-stage restrictive lung disease. Furthermore, while the presence of asbestos bodies in tissue sections is a sensitive and specific marker of asbestos exposure, neither this finding nor any other charge is a marker indicative of asbestosis or the severity of asbestosis. With the enactment of the Asbestos Standard in the United States, asbestos exposures have been decreasing in this country. However, industries that produce asbestos products and wastes continue to expand in developing countries. Prevention of asbestos-related lung disease should be a global endeavor, and asbestos exposures should be regulated in both developed and developing countries.
Nobility
Authors: James S. Goodwin
Journal: Annals of Internal Medicine (2001)

On Being a Doctor3 April 2001NobilityJames S. Goodwin, MDJames S. Goodwin, MDDr. Goodwin: Galveston, TX 77555-0460Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-7-200104030-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Some years ago, my wife and I conducted a study of medical patients who were disliked by their physicians (1). The hardest part was getting the physicians to admit that they harbored any such emotions. “I like all my patients,” was a frequent reply.Not me. I have never had trouble disliking patients. One could say that I have a highly developed sense of dislike, so acute that I sometimes use it as a diagnostic tool. When confronted with a patient I dislike, I screen for depression and alcohol abuse because I'd otherwise invariably miss those diagnoses, and I am ...Reference1. Goodwin JM, Goodwin JS, Kellner R. Psychiatric symptoms in disliked medical patients. JAMA. 1979;241:1117-20. [PMID: 0000762762] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Dr. Goodwin: Galveston, TX 77555-0460Corresponding Author: James S. Goodwin, MD, Department of Internal Medicine and Sealy Center on Aging, The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0460; e-mail, [email protected]edu PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 3 April 2001Volume 134, Issue 7Page: 621-622KeywordsBreast cancerCardiovascular therapyEmotionsMotivationNursesOsteoporosisStomachStrokeSurgerySystematic reviews ePublished: 3 April 2001 Issue Published: 3 April 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Authors' Reply
Authors: Harri Hemilä, Robert M Douglas
Journal: PLoS Medicine (2005)

Covering 60 years of research without mentioning a paper that highlights fl aws in the literature, in a review, should negate any conclusion.In the Cochrane review by Douglas et al. [1], which is referenced in the Best Practice article by Douglas and Hemilä [2], there was no mention of the revealing paper published last year by Padayatty et al. [3], which shows that three-times greater blood concentration can be achieved with an oral dose of vitamin C than previously thought possible.Since viruses increase the demand for ascorbic acid, the oral doses used in the reviewed studies appear trivial, and would not be expected to produce any positive effect.Compare human oral dose studies to what animals synthesize throughout the day.It is obvious that a single dose of a watersoluble vitamin, regardless of the number of milligrams consumed, will not elevate blood plasma levels enough to produce a preventive or therapeutic effect.
Coexistence of Prader-Willi syndrome, congenital ectropion uveae with glaucoma, and factor XI deficiency
Authors: W. Futterweit
Journal: JAMA (1986)

A patient with Prader-Willi syndrome and unilateral congenital ectropion uveae with glaucoma was found to have factor XI deficiency and reduced levels of serum luteinizing hormone, follicle-stimulating hormone, and testosterone. Administration of gonadorelin (LH-RH) increased serum levels of luteinizing hormone and follicle-stimulating hormone, while clomiphene citrate had no effect, suggesting a primary hypothalamic defect. Patients with congenital ectropion uveae should be followed up for the development of both glaucoma and neural crest disorders. (<i>JAMA</i>1986;255:3280-3282)
Hypothermia in the Aged
Authors: Steven M. Horvath, Robert D. Rochelle
Journal: Environmental Health Perspectives (1977)

Body temperature is maintained by a balance between heat production and heat loss. Temperature regulation consequent to exposure to a cold environment appears to be modified in elderly persons. An evaluation of the physiological adjustments made by older individuals is presented. It is apparent that hypothermia can develop in the older population as a consequence of modifications in both behavioral and physiological responses to cold exposure. With the growing awareness of an energy shortage with consequent lower ambient temperatures in homes, there is a need to obtain adequate information as to the physiological capabilities and adaptive potential of elderly individuals to a cold stress.
SHOCK AS A CURATIVE AGENT.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BRAZIL
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fluvastatin in Acute Myocardial Infarction: Effects on Early and Late Ischemia and Events: the FLORIDA Trial
Authors: A. Liem, A. J. van Boven, A. P. Withagen, R. M. Robles de Medina, N. J. G. M. Veeger, J. G. P. Tijssen
Journal: Circulation (2000)
Do HIV Subtypes Direct Epidemics?
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 324: BRAF/MEK inhibitors selectively prime melanoma for Mcl-1 dependence and sensitize to Mcl-1 inhibition
Authors: Karson J. Kump, Lei Miao, Nurul Ansari, David B. Lombard, Zaneta Nikolovska-Coleska
Journal: Cancer Research (2019)

Abstract Frontline treatment for patients diagnosed with metastatic melanoma harboring a V600 BRAF mutation is a combination of BRAF/MEK inhibitors. Despite advances in targeted therapies used to treat melanoma, the majority of patients will relapse due to acquired resistance. The intrinsic apoptotic pathway is frequently dysregulated in cancer, promoting cell survival and resistance mechanisms. The anti-apoptotic Mcl-1 protein was identified as a key resistance factor to vemurafenib, a mutant BRAF inhibitor, and likely plays a role in preventing apoptosis in the context of dual BRAF/MEK inhibitor resistance. Activation of apoptosis by using small molecule inhibitors of the anti-apoptotic Bcl-2 proteins has become a validated therapeutic approach and can re-sensitize cancers to standard of care treatments. We found that melanoma cell lines display a heterogeneous dependency on anti-apoptotic proteins. In this study, we systematically investigated the role of Mcl-1 in vemurafenib resistance in melanoma cell lines using genetic and pharmacological inhibition of Mcl-1. Using the functional BH3 profiling assay, we discovered that melanoma cell lines resistant to vemurafenib are increasingly primed for Mcl-1 dependence. Additionally, applying dynamic BH3 profiling we demonstrated that melanoma cell lines subjected to short term treatment with vemurafenib showed greater dependency upon Mcl-1 for survival, thus serving as a selective priming agent. Consistent with these findings, both vemurafenib resistant and short-term vemurafenib pre-treated melanoma cell lines displayed increased sensitivity to Mcl-1 genetic silencing using siRNA and direct Mcl-1 inhibition using small-molecule inhibitors developed by our group. We further demonstrate significant synergy in the induction of apoptosis induced by the combination of vemurafenib and Mcl-1 inhibitors such as UM-101. In a similar way, Mcl-1 priming and increased sensitivity to Mcl-1 inhibitors was shown in melanoma cells pre-treated with MEK inhibitors. We further studied the mechanism of apoptosis induced by Mcl-1 inhibitors and validated their cellular target engagement. These studies provide evidence that targeting Mcl-1 represents a promising therapeutic strategy for treating patients with resistant melanomas and aids in the design of rational combination therapies before resistance is acquired. Citation Format: Karson J. Kump, Lei Miao, Nurul Ansari, David B. Lombard, Zaneta Nikolovska-Coleska. BRAF/MEK inhibitors selectively prime melanoma for Mcl-1 dependence and sensitize to Mcl-1 inhibition [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 324.
'Black lung' takes toll in suffering, not death
Authors: V. S. Cowart
Journal: JAMA (1982)

Although coal workers' pneumoconiosis (CWP) has been found in 70% to 80% of subjects in the ongoing National Coal Workers Autopsy Study (NCWAS), it has been considered as the underlying cause of death in only 4.2%. Thus, while there can be no doubt that CWP, or "black lung," is prevalent in the coal mining population, it seems more likely to cause pain and suffering than actual death. The ten-year NCWAS experience was presented at a recent international conference on occupational lung disease in Chicago sponsored by the American College of Chest Physicians. The report was given by Francis H. Y. Green, MD, a pathologist with the National Institute for Occupational Safety and Health at Morgantown, WVa. The voluntary autopsy study, Green said, was initiated under a 1969 law intended primarily to provide services to survivors of miners who were seeking to establish evidence for black lung benefit claims. Since the